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Abstract. In 36 healthy control subjects (21 females, I5 males; age range 18-65 
years; mean age 41.8 years, SD 15.6 years), a bedtime dose of I.5 mg RS 86, an 
orally acting cholinergic agonist, shortened rapid eye movement (REM) latency, 
increased REM sleep, and decreased slow-wave sleep. Six of the subjects (> 40 
years old) even displayed sleep-onset REM periods after the drug. Results of the 
present study agree well with those of studies using other cholinomimetics (i.e., 
physostigmine, arecholine) and confirm the importance of the cholinergic system 
for REM sleep regulation. Since RS 86 mimicked some of the REM sleep 
abnormalities specific for patients with depressive disorders, the cholinergic 
system may play a role in the pathogenesis and pathophysiology of depressive 
diseases. 
Key Words. RS 86, cholinergic system, rapid eye movement sleep, depression. 
Much attention has focused on the “reciprocal interaction model of sleep regulation” 
(Hobson et al., 1975; McCarley and Hobson, 1975) as an explanation of the 
cyclic changes of non-rapid eye movement (NREM) and rapid eye movement 
(REM) periods during sleep. According to this theory, the regular patterning of 
NREM/ REM sleep is governed by cell groups located in the brainstem. Neurons in 
the locus ceruleus (via norepinephrinergic neurotransmission) are said to inhibit 
REM sleep, whereas neurons mainly in the pontine reticular formation (excited by 
acetylcholine and using it as a neurotransmitter) are believed to promote REM sleep. 
Reciprocal interaction between these transmitter systems is assumed to be 
responsible for the temporal structure of NREM/ REM sleep. Empirical evidence for 
this theory is based on both animal and human studies. Direct injection of carbachol, 
an acetylcholine agonist, into the pontine reticular formation in cats reduced REM 
latency (= time from sleep onset to the occurrence of the first REM period), 
increased REM period duration, and heightened amounts of REM sleep (for 
overview, see Hobson et al., 1986). 
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Such interaction in humans was tested with the cholinomimetic agents 
physostigmine and arecholine (for overview, see Sitaram et al., 1984). Intravenous 
administration of physostigmine or arecholine during the first or the second NREM 
period prompted an advance of the following REM period. These drugs are, 
however, accompanied by such practical limitations as a very short half-life, thus 
entailing protracted routes of administration like i.v. infusion during sleep. In ad- 
dition, they have nonspecific effects on both central and peripheral muscarinic cho- 
linergic receptors (physostigmine acts on nicotinic receptors as well), necessitating 
pretreatment with a peripheral muscarinic blocker like methylscopolamine. 
Spiegel (1984) studied an alternative cholinergic agonist, RS 86. This orally acting 
muscarinic agonist has a half-life of about 8 hours (for pharmacology of RS 86, see 
Palacios et al., 1986) and minor side effects. RS 86, 1.5 mg, administered p-o. to 
young healthy volunteers, disinhibited REM sleep during the first third of the night 
(i.e., shortened REM latency and increased REM sleep%) and reduced slow-wave 
sleep (SWS) during the first two two-thirds of the night (Spiegel, 1984). 
These results are of special interest for psychiatric research in depression, because 
the effects of RS 86 on sleep parameters in healthy controls mimic some of the sleep 
abnormalities characteristic of depression, such as shortened REM latency, 
prolonged duration and heightened density of the first REM period, and reduced 
SWS activity (for overview, see Gillin et al., 1984). 
If these results are linked to the “cholinergic-adrenergic” hypothesis of mania and 
depression (Janowsky et al., 1972), which states that mania and depression are 
caused by a central nervous system (CNS) imbalance between the cholinergic and 
noradrenergic transmitter systems, REM sleep abnormalities in depression could be 
interpreted as indirect evidence of a pathophysiologically relevant dysregulation of 
neurotransmitters in depression (McCarley, 1982). 
The aim of the present study was to replicate Spiegel’s (1984) findings in a larger 
sample of healthy volunteers that included subjects of both sexes and older age 
groups and was thus more comparable to samples of depressed patients. 
Methods 
Design. RS 86, 1.5 mg, was chosen as an appropriate dose to influence sleep (see Spiegel, 
1984). Subjects slept in the laboratory for 3 nights, with night I serving for adaptation to the 
laboratory. Placebo or RS 86, I .5 mg, was administered in a double-blind, randomized design 
at 2200 h, on nights 2 and 3. 
Subjects. Thirty-six subjects (male n = 15; female n = 21) agreed to participate in the study 
and were paid for their services. Their mean age was 41.8 years (SD 15.6 years; range 18-65 
years). Before being included in the study, subjects were thoroughly screened for physical and 
psychiatric disorders. They underwent a physical examination, electrocardiogram, drug 
screening, and an extensive psychiatric interview encompassing personal and family history of 
psychiatric disorders. Only subjects who were free of medical and psychiatric disorders and 
had no family history of affective disorders were included. Subjects received detailed 
information about the experimental procedures and possible side effects of the drug. 
Mood Assessment. Before retiring and after waking up in the morning, subjects completed 
an adjective checklist, the AMS (von Zerssen, 1986) to gauge mood. 
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Sleep. Sleep was recorded between lights out (2315h) and lights on (0630h) using standard 
procedures: horizontal electro-oculogram (EOG), submental electromyogram (EMG), and 
electroencephalogram (EEG) (($-A,; C,-A,). Records were scored without knowledge of 
experimental condition by two experienced raters according to standardized criteria (Recht- 
schaffen and Kales, 1968). 
The following sleep parameters were evaluated: (I) Sleep efficiency: ratio of total sleep time 
(TST) to time in bed (TIB) X 100%. (2) Stages Wake, I, 2, SWS (Stages 3 and 4 combined), 
and REM (expressed in % of sleep period time (SPT), i.e., time from sleep onset until final 
awakening). (3) Latencies, i.e., time from beginning of the record to the first occurrence of 
Stage 2 (= sleep onset latency) and from sleep onset to the first occurrence of stage REM 
(= REM latency) (in min). (4) Number of awakenings during SPT. (5) Early morning 
awakening (EMA) (in min), i.e., time span between the last epoch of Stages 2, 3, 4, REM 
occurring during the record and before lights on in the morning. (6) Number of REM periods. 
(7) Duration of REM periods (in min). (8) NREM intervals: time span between REM periods 
(in min). (9) REM density for each REM period and for the whole night (REM density= the 
ratio of 3-see mini-epochs per REM period including rapid eye movements to the total 
number of all 3-set mini-epochs per REM period X 100%). 
Statistics. Descriptive statistical parameters include presentation of mean, standard 
deviation, and median. For comparisons between placebo and drug conditions, non- 
parametric methods were used: the Wilcoxon Test for dependent samples and the Mann- 
Whitney Cl test for independent samples. The Spearman rank-correlation coefficient served to 
assess correlations. To determine the differential effects of age and gender on sleep variables 
during placebo and drug conditions, a two-way analysis of variance (ANOVA) was conducted 
with the factors experimental condition (placebo vs. RS 86) gender (male vs. female), and age 
(< 40 years vs. > 40 years). For all calculations, the level of significance was set at 5% 
(two-tailed). 
Results 
Effects of RS 86 on Sleep. Table 1 displays results for the variables of sleep 
continuity, sleep architecture, and REM sleep for the whole sample, comparing 
placebo and drug condition. RS 86, 1.5 mg, did not influence any parameter of sleep 
continuity. Regarding sleep architecture, the drug night was accompanied by a 
reduction in Stage 1 and SWS (% SPT). REM sleep parameters were influenced in 
the expected manner. Mean REM latency was reduced by approximately 17 min (p 
< 0.01) and Stage REM (% SPT) was enhanced by about 4% 0, < 0.001). RS 86 had 
no influence on overall REM density and had no effect on the REM density of any of 
the first four REM periods. Fig. 1 illustrates the impact of 1.5 mg RS 86 on the 
NREM/REM pattern until the end of REM period 4 (succeeding cycles were 
omitted due to decreasing case numbers). 
As mentioned above, REM latency (expressed as NREM,) was shortened during 
the drug condition. The second NREM interval was also decreased @ < 0.001). 
REM period 1 was slightly but not significantly lengthened after RS 86, while the 
length of REM period 2 was shortened in comparison to placebo 0, < 0.05). 
RS 86 significantly @ < 0.001) enhanced the mean (+ SD) number of REM 
periods in comparison to placebo (placebo: 3.8 + 0.8; RS 86: 4.4 + 0.7). 
Effects of RS 86 on Mood. Table 2 summarizes the results for mood assessment. 
As shown, RS 86 had no influence on parameters of well-being compared to placebo. 
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Table 1. Influence of RS 86 on sleep in comparison with placebo in 36 
healthy controls (mean f SD, median in parentheses) 
RS 86 Wilcoxon test 
Sleep variables Placebo (1.5 rw) (2-tailed) 
Sleep continuity 
Sleep efficiency (%) 
S-2 latency (min) 
Time awake (% sleep period time) 
No. wakenings 
Early morning awakening (min) 
Sleep architecture 
Stage 1 (% sleep period time) 
Stage 2 (% sleep period time) 
SWS (% sleep period time) 
Rapid eye movement sleep 
REM latency (min) 
REM (% sleep period time) 
REM density (%, whole night) 
88.3 + 8.2 
(90.1) 
20.7 zt 17.2 
(14.8) 
6.0 + 6.0 
(3.5) 
8.7 rt 5.6 
(8.0) 
5.2 f 13.2 
(0.5) 
8.5 + 5.2 7.5 * 4.2 
(6.7) (6.3) 
55.4 + 7.6 56.0 + 9.3 
(54.3) (55.1) 
10.6 zt 9.7 7.3 * 7.9 
(8.2) (4.6) 
72.7 ?z 26.2 
(68.0) 
18.2 + 4.0 
(18.2) 
28.1 & 10.8 
(26.6) 
88.4 f 7.5 
(90.9) 
19.4 + 12.0 
(17.0) 
6.2 + 5.4 
(5.2) 
8.8 + 5.6 
(8.0) 
4.7 f 10.2 
(0.5) 
55.9 t 36.3 
(45.3) 
21.9-t 5.8 
(22.4) 
26.8 I!C 11.4 
(25.3) 
NS 
NS 
NS 
NS 
NS 
p < 0.05 
NS 
p < 0.001 
p < 0.01 
p < 0.001 
NS 
Fig. 1. Effects of RS 86 (1.5 mg) vs. placebo on the non-REM-REM cycle in 
36 healthy controls 
73’ 17’ 89’ 29’ 75’ 29’ 65’ 26 
Placebo NREMl NREtl2 
NREMj w NREML fil 
56”’ 21’ 69”” 22” 69’ 29’ 65’ 20’ 
1.5 mg RS 86 NREMt 
NREM2 m NREtl3 w NREML w 
Sleep Onset 100 2;Jo 3Ao 4;)Omin. 
Time asleep (min.1 
Note. REM = rapid eye movement. Length of open bars represents non-REM periods. Length of shaded bars 
represents REM periods. Bar width represents SD (same scale for x- and y-axis). Asterisks indicate level of 
statistical sigmflcance (Wilcoxon test, P-tailed) comparing placebo and RS 86: * p < 0.05; ** p < 0.01; 
*** p < 0.001. 
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Table 2. Influence of RS 86 on psychometric measurements in comparison 
with placebo in 36 healthy subjects (mean f SD, median in parentheses) 
RS 88 Wilcoxon test 
Placebo (1.5 mg) (2-tailed) 
AMS evening 17.9 f 8.2 19.7 + 8.1 NS 
(19.0) (19.0) 
AMS morning 16.4 * 9.0 16.9 + 9.3 NS 
(16.0) (19.0) 
AMS = adjective checklist to assess mood (van Zerssen. 1966). 
Effects of Age and Gender. Fig. 2 illustrates the effect of RS 86 on REM latency 
when the sample was dichotomized by age: < 40 years (5 males, 8 females) vs. > 40 
years (10 males, 13 females). The mean (+ SD) REM latency in the younger age 
group decreased from 7 I .O k 27.2 min to 61.1 f 30.7 min after RS 86 (p < 0.05), and 
this effect was even more pronounced in the older age group, with a decrease from 
73.6 k 26.1 min to 52.8 f 39.4 min (p < 0.01). 
Six of the 23 older subjects (5 females), as compared with none of the younger 
subjects, showed a REM latency < 25 min (SOREMP = sleep onset REM period) 
after RS 86. However, when REM latency for the whole sample was correlated with 
age for placebo, RS 86, and the A REM latency between the two conditions, the 
Fig. 2. REM latencies for placebo and drug condition comparing young 
(I 40 years) and old subjects (> 40 years) 
Age d 40 yrs. 
tn.131 
min . 
0 
P RS66 
Note. REM = rapid eye movement. Arrows mark medians 
min 
140- 
100- 
E _ 
5 
3 
i - 
E _ 
so- 
O- 
Age > 40 yrs. 
h.23) 
P RS66 
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following nonsignificant coefficients emerged: placebo, r = -0.05; RS 86, r = -0.26; 
A REM latency, r = -0.13 (Spearman rank correlation). When A REM latency 
(placebo - RS 86) was compared between the two age groups, no significant 
difference emerged (U test). A Fisher Exact Test comparing the occurrence of 
SOREMPs between the two age groups yielded an error probability of p = 0. IO. 
Upon closer scrutiny of Fig. 2, it does not seem surprising that no statistically 
verifiable higher responsiveness to the cholinergic stimulus occurred in the older 
subjects. As opposed to the six subjects with extremely shortened REM latency, five 
of the older volunteers displayed a moderate to marked delay of the first REM 
period after RS 86 in comparison to placebo. The same held true for 2 of the 13 
younger subjects. 
In an attempt to elucidate this paradoxical, unexpected lengthening of REM 
latency, the first NREM periods of all subjects were analyzed for the number of 
awakenings and Stages 1,2, and SWS (min). Results from an earlier study (Berger et 
al., 1983) indicated that possible REM-inducing properties of cholinomimetics may 
be masked by sleep disruptions in some subjects due to the arousing properties of 
these drugs. Table 3 presents the number of awakenings and distribution of Stages 
Wake, I, 2, and SWS separately for subjects with a shortened or lengthened REM 
latency after RS 86. Subjects with a shortened REM latency showed a decreased 
number of awakenings and duration of every sleep stage during NREM period I 
(statistically significant for Stage 2 and SWS). On the other hand, the seven subjects 
with a lengthened REM latency showed an increased number of awakenings, 
increased amounts of sleep Stages I, and 2, and decreased SWS. The increase in 
Stages I and 2 (min) reached statistical significance, whereas there was only a strong 
tendency toward heightened Stage Wake after RS 86 during NREM period I. The 
individual values of Wake time (min) after RS 86 were 0,4,6, 12, 14.5,25.5, and 32.5 
min, indicating sleep disruption and heightened arousal in almost all of these 
subjects. 
To evaluate age effects on all of the sleep variables, a two-way ANOVA was 
conducted with experimental condition (placebo vs. RS 86) and age (< 40 years vs. 
> 40 years) as factors. There were clear-cut age effects for many of the sleep 
variables. Sleep efficiency decreased, latency to Stage 2 increased, as did time awake 
(% SPT) and the number of awakenings in the older age group. The older subjects 
spent more time in Stage 1 (70 SPT) and less time in SWS (o/o SPT). REM density 
was diminished for the older subjects. 
Effects due to experimental conditions were a reduction in SWS (% SPT) and 
REM latency, and an enhancement of REM sleep (o/o SPT). There were no 
significant interaction effects between age and experimental condition. 
With regard to the effects of the experimental conditions and gender (male vs. 
female), no significant results were observed. 
Discussion 
Our results concerning the influence of mg RS 86 on sleep in healthy subjects 
correspond well to those of other studies testing the effects of cholinomimetic agents 
on NREM/REM regulation. A dose of 1.5 mg RS 86 caused a reduction of REM 
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latency comparable to that provoked by physostigmine (Sitaram et al., 1976, 1977; 
Berger et al., 1983), arecholine (Sitaram et al., 1978a, 19786), and RS 86 (Spiegel, 
1984). 
These results provide support for the hypothesis of a central cholinergic 
involvement in the regulation of REM sleep in humans. In comparison to the other 
cholinomimetic agents, which require more elaborate experimental designs, RS 86 
offers a more convenient way of testing cholinergic involvement in the regulation of 
REM sleep. Its pharmacological properties (see Palacios et al., 1986) permit 
investigation of larger samples of control subjects and patients. 
Though characterized by a long half-life, RS 86 exerted its effect on REM sleep 
mainly at the beginning of the night. RS 86 enhanced REM sleep (Yc SPT) by 3.7% in 
comparison to placebo, though in view of the cyclic structure of NREM/REM 
patterns (see Fig. I), it is evident that this effect is due to the shortening of the first 
(= REM latency) and second NREM periods, which led to a shift in the first 
REM-NREM cycle and thus to a heightened propensity for further REM periods to 
occur at the end of the night. In our study, RS 86 did not prolong the length of REM 
periods 1, 3, or 4, but it did induce a shortening of REM period 2, contrary to our 
expectation. This phenomenon is difficult to explain, especially in view of the long 
half-life of the drug. It may be speculated that counterbalancing reactions of those 
transmitter systems regulating the NREM/ REM pattern neutralized the cholinergic 
impact. In accordance with all the other studies of cholinomimetics, RS 86 did not 
influence phasic aspects (i.e., eye movement density) of REM sleep. SWS (To SPT) 
was significantly reduced by RS 86. The decrease in SWS might be due to arousing 
properties of RS 86, an effect typical of all cholinergic agonists (Berger et al., 1983). 
One explanation for shortened REM latencies, proposed by Borbely and Wirz- 
Justice (1982) stated that the reduction of SWS in depression (as measured by the 
power in the delta frequency band), due to a deficiency of process “S,” may be the 
primary cause for REM sleep disinhibition at the beginning of the night. However, 
results of our studies (Berger et al., 1982, in press), as well as of studies of Van den 
Hoofdakker and Beersma (1985) do not support this hypothesis. Berger et al. (1982) 
found no correlation between REM latency and the amount of SWS in 45 depressive 
patients. In another study, Berger et al. (in press) showed that nine remitted 
depressives exhibited a highly significant reduction of SWS following 1.5 mg RS 86, 
which was not accompanied by a significant shortening in REM latency. Van den 
Hoofdakker and Beersma (1985) also failed to find a relationship between REM 
latency and power in the delta frequency band (an even better estimate of SWS 
activity) in their sample of depressed patients. Therefore, it can be assumed that the 
shortening of REM latency observed in the present study was directly due to the 
REM-sleep-related properties of RS 86. However, our results can provide only 
indirect evidence against the hypothesis of Borbely and Wirz-Justice (1982), since the 
SWS analysis was performed visually. 
None of the sleep variables under investigation showed a significant gender-related 
effect. As for an age effect, baseline sleep data differed in the expected direction 
between the young and old subjects, confirming results reported in the literature 
(Williams et al., 1974; Feinberg, 1976). 
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There were no significant interaction effects between age and drug condition. RS 
86 caused SOREMPs in a subgroup of six (25%) of the 23 older subjects. None of 
these subjects showed any psychopathological features. Absence of lifetime or family 
history of affective disorders had been established in prestudy interviews of the 
probands. 
First-degree relatives were not interviewed directly-a necessary step, according to 
Gershon and Guroff (1984) in validating patients’ or volunteers’ statements about 
positive or negative family history. Therefore, it cannot be stated with finality that 
these subjects had no family history of affective disorders. Regarding the mood 
scores of these six subjects under RS 86 in comparison to placebo, no change was 
noted. Their placebo REM latencies were in the normal range (see Fig. 2) ruling out 
a preexisting elevation of their baseline level of cholinergic activity. Gillin et al. 
(1981) demonstrated that REM latency decreased as a function of age in both 
healthy subjects and depressed patients, being more pronounced in the latter group. 
They hypothesized that many of the sleep abnormalities found in depressive patients 
might be caused by a reversible process of premature aging in this group of patients. 
Our finding of a higher responsiveness of the REM sleep system to a cholinergic 
stimulus in a subgroup of older subjects could be interpreted as suggesting 
comparable changes in the neurotransmitter regulation of REM sleep during the 
physiological process of aging and in depression. 
On the other hand, a paradoxical delay of REM latency after RS 86 was observed 
in seven of the subjects, five of whom belonged to the older group. A detailed 
analysis of their first NREM cycles suggested that in this group the administration of 
RS 86 led to an initial sleep disruption with more awakenings, Stage Wake, and 
Stage 1 at the beginning of the night. 
In summary, the effects of RS 86 on REM sleep in control subjects mimic some of 
the sleep abnormalities of depressive patients, thereby providing further indirect 
evidence of the cholinergic-aminergic hypothesis of REM sleep disinhibition and 
depression (Janowsky et al., 1972; McCarley, 1982). 
In view of the facts that almost all antidepressant agents suppress REM sleep (for 
overview, see Chen, 1979), that the initial amount of REM sleep suppression during 
drug treatment may be a predictor of therapeutic outcome (Kupfer et al., 1983; 
Hochli et al., 1986), and that naps after successful sleep deprivation including REM 
sleep may lead to an immediate relapse (Wiegand et al., 1987) investigations of the 
neuronal and neurochemical processes responsible for the regulation of REM sleep 
are highly relevant. The cholinomimetic drug RS 86 seems to provide a useful tool 
for these investigations. 
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